GLUCOPHAGE
Total Payments
$12.1M
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $2.5M | 1 | 0 |
| 2018 | $5.9M | 1 | 0 |
| 2017 | $3.7M | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.1M | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Metformin The Glycemia Reduction Approaches in Diabetes | E.R. Squibb & Sons, L.L.C. | $12.1M | 0 |
Top Doctors Receiving Payments for GLUCOPHAGE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Bethesda, MD | $12.1M | 3 |
Ad
Manufacturing Companies
- E.R. Squibb & Sons, L.L.C. $12.1M
Product Information
- Type Drug
- Total Payments $12.1M
- Total Doctors 0
- Transactions 3
About GLUCOPHAGE
GLUCOPHAGE is a drug associated with $12.1M in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is E.R. Squibb & Sons, L.L.C..
Payment data is available from 2017 to 2019. In 2019, $2.5M was paid across 1 transactions to 0 doctors.
The most common payment nature for GLUCOPHAGE is "Unspecified" ($12.1M, 100.0% of total).
GLUCOPHAGE is associated with 1 research study, including "Metformin The Glycemia Reduction Approaches in Diabetes" ($12.1M).